Document is current
Any future updates will be listed below
-
Authors
Papanastasiou, Evangelos http://orcid.org/0000-0002-8029-666X
Mouchlianitis, Elias
Joyce, Dan W.
McGuire, Philip
Boussebaa, Celia
Banaschewski, Tobias http://orcid.org/0000-0003-4595-1144
Bokde, Arun L. W.
Büchel, Christian
Quinlan, Erin
Desrivières, Sylvane http://orcid.org/0000-0002-9120-7060
Flor, Herta
Grigis, Antoine
Garavan, Hugh
Spechler, Philip
Gowland, Penny
Heinz, Andreas
Ittermann, Bernd
Martinot, Marie-Laure Paillère
Artiges, Eric http://orcid.org/0000-0003-4461-7646
Nees, Frauke
Orfanos, Dimitri Papadopoulos http://orcid.org/0000-0002-1242-8990
Paus, Tomáš
Poustka, Luise
Millenet, Sabina
Fröhner, Juliane H. http://orcid.org/0000-0002-8493-6396
Smolka, Michael N. http://orcid.org/0000-0001-5398-5569
Walter, Henrik http://orcid.org/0000-0002-9403-6121
Whelan, Robert
Schumann, Gunter http://orcid.org/0000-0002-7740-6469
Shergill, Sukhwinder S.
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (695313)
Innovative Medicines Initiative (115300-2)
RCUK | Medical Research Council (MR/N000390/1)
Svenska Forskningsrådet Formas
DH | NIHR | Research for Patient Benefit Programme
Bundesministerium für Bildung und Forschung (01GS08152)
Fondation de France
Fondation pour la Recherche Médicale (DPA20140629802)
Fondation de l'Avenir pour la Recherche Médicale Appliquée
- License Information
-
More Information
Article History
Received: 21 May 2019
Accepted: 24 February 2020
First Online: 20 March 2020
Competing interests
: Dr. Evangelos Papanastasiou was supported by an NIHR BRC (National Institute for Health Research, Biomedical Research Council) Clinical Disorder Pilot Funding Award (2012–2013), and an NIHR CLAHRC (Collaboration for Leadership in Applied Health Research and Care) South London fee support award (2015–2016). He was an employee of Mundipharma Research and Lundbeck. Dr. Dan W. Joyce is supported by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005). Prof. Tobias Banaschewski served in a paid advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Lundbeck, Medice, Novartis, Shire. He received conference support or speaker’s fee by Lilly, Medice, Novartis, and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. Dr. Henrik Walter received a speaker honorarium from Servier (2014). Prof. Sukhwinder S. Shergill is supported by a European Research Council (ERC) Consolidator Award and by the NIHR South London and Maudsley Biomedical Research Centre (BRC). The other authors report no biomedical financial interests or potential conflicts of interest.
